Prolonged Untreated and Treated Course of a Malignant Melanoma

Nashan, Dorothée; Haufs, Michael G.; Kleinheinz, J.; C, Al-Dandashi; Bruckner‐Tuderman, Leena

doi:10.1159/000089034

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 76 melanoma patients with cerebral metastases the addition of whole-brain irradiation to fotemustine revealed a benefit in the cerebral progression time compared to fotemustine alone, but no significant impact on survival (105 vs. 86 days) was noted [8]. As the combination of chemotherapeutic agents with radiotherapy is feasible and reports of long-term survival even in patients with brain metastases exist [29], the therapeutic options in this patient subgroup should be planned in detail individually.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Impact of Treatment in Melanoma Brain Metastases: Better Prognosis for Women?

Hofmann¹,

Coll²,

Küchler

et al. 2007

Dermatology

View full text Add to dashboard Cite

Background: Brain metastases are a common consequence in patients with stage IV melanoma associated with a grim prognosis. Objective: The objective of this study was the examination of prognostic factors and the evaluation of different treatment options. Methods: A consecutive series of 133 patients with melanoma brain metastases with regard to prognostic factors and the impact on survival were analyzed. Results: 82 patients had involvement of only the cerebrum at the initial diagnosis, whereas in 7 patients only the cerebellum and the brainstem were involved. Seizures (n = 29) were the single most often reported symptom. The overall median survival time was 24 weeks (1–196) from diagnosis of brain metastases. Women had a significantly longer survival with 36 weeks (3–196) compared to 17 weeks (1–159) for men. Multivariate analysis has established as significant prognostic factors: female gender, number of brain metastases, surgery, chemotherapy, radiotherapy and corticosteroid application. Conclusion: With regard to the prognostic factors, an improved survival can be achieved in this patient group using more elective treatment options, also with emphasis on corticosteroids.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Impact of Treatment in Melanoma Brain Metastases: Better Prognosis for Women?

Hofmann¹,

Coll²,

Küchler

et al. 2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…They defined this time as the delay between excision of the melanoma and the first time the patient noticed it for lesions of less than 5 years' duration or as the delay between excision and the first changes for lesions previously stable for more than 5 years. This is an approximation of tumor growth, as some melanomas will probably not visibly evolve for years or evolve for more than 5 years, 6 and their growth rate will prob-ably not be constant. Still, it is a clinically relevant marker, as previously shown by Grob et al 7 However, the only way to assess this delay is to rely on the patient's or the family's memory.…”

Section: How Frequent Are Fast-growing Melanomas and How Can We Recomentioning

confidence: 99%

Growth Rate, Early Detection, and Prevention of Melanoma

Lipsker¹

2006

Arch Dermatol

View full text Add to dashboard Cite

“…The breakthrough in the treatment of this malignancy, especially in advanced stages, has not been found yet [2, 3] and cases of prolonged untreated and treated courses in metastatic disease are rare [4]. Looking at the worldwide incidence patterns, cutaneous melanoma is a disease of people living in developed countries with a continuing rise in incidence in nearly all age groups and both genders in Europe, the United States, Australia and New Zealand [1].…”

Section: Introductionmentioning

confidence: 99%

Clinical Epidemiology of Invasive Cutaneous Malignant Melanoma in the Austrian Province Styria in the Years 2001–2003 and Its Relationship with Local Geographical, Meteorological and Economic Data

Richtig

Berghold²,

Schwantzer³

et al. 2007

Dermatology

View full text Add to dashboard Cite

Background:Melanoma incidence rates vary within Europe. The highest incidences are reported in Scandinavia, the lowest in the southern parts, but incidences themselves also vary within the different countries. Objective:We investigated the incidence of invasive cutaneous melanoma in Styria, a province of Austria, in the years 2001–2003. Methods:Data from 1,082 patients, 511 males and 571 females (mean age 58.2 years) with primary melanoma were collected. For each patient, information regarding residence was available, and therefore the geographic distribution of melanoma on district level was investigated with particular reference to the mean number of sun hours, mean altitude, number of companies with more than 200 employees and median income. Results:The mean annual incidence (age-standardized rate) was 24.5 per 100,000 (95% CI: 22.4–26.6), lifetime risk 1 in 52. Districts with a higher number of sun hours and higher altitude showed lower melanoma incidences. Higher median income was associated with higher melanoma incidence (p < 0.001). Conclusion:The high incidence of invasive melanoma in Styria is unclear and a causal relationship between higher income and melanoma incidence remains speculative. Further investigations, especially concerning lifestyle and environmental factors, may unravel additional causative factors.

show abstract

Prolonged Untreated and Treated Course of a Malignant Melanoma

Cited by 3 publications

References 16 publications

Prognostic Factors and Impact of Treatment in Melanoma Brain Metastases: Better Prognosis for Women?

Prognostic Factors and Impact of Treatment in Melanoma Brain Metastases: Better Prognosis for Women?

Growth Rate, Early Detection, and Prevention of Melanoma

Clinical Epidemiology of Invasive Cutaneous Malignant Melanoma in the Austrian Province Styria in the Years 2001–2003 and Its Relationship with Local Geographical, Meteorological and Economic Data

Contact Info

Product

Resources

About